Drug profile · INN
daridorexant
QUVIVIQ
daridorexant (QUVIVIQ) is a orexin receptor antagonist.
EMA: approved NMPA: clinical trials Nervous system (N05) N05CJ03
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — daridorexant
- Class
- Nervous system (N05)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
daridorexant (QUVIVIQ) is a orexin receptor antagonist.
Key facts
INN daridorexant
Brand QUVIVIQ
Mechanism Orexin receptor antagonist
Target Orexin receptor
Therapeutic class Nervous system (N05)
ATC code N05CJ03
Mechanism of action
Orexin receptor antagonist
Primary target: Orexin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is daridorexant?
daridorexant (QUVIVIQ) is a orexin receptor antagonist.
What is the brand name for daridorexant?
QUVIVIQ is a marketed brand name for daridorexant. Check FDA Drugs@FDA for the current US label holder and prescribing information.